February 17, 2017
Webinar
In January 2017, the U.S. Food and Drug Administration (FDA) released a highly anticipated draft guidance detailing the agency’s expectations for demonstrating biosimilar interchangeability with a reference product and final guidance on nonproprietary naming of biological products. The interchangeability guidance provided more insight into the evidence required to meet the standard for an interchangeability rating, including the scientific justification for extrapolation from one condition of use to another, the recommended framework for switching studies between the reference product and the proposed interchangeable product, and the considerations for determining when post-marketing data is needed. With billions of dollars at stake, how do the new guidelines affect approved and soon-to-be reviewed biosimilar products? What are the best practices for interfacing with the FDA prior to and during the approval process? How might the Trump administration’s policies impact the FDA approval process for biologics, biosimilars, and interchangeables?
The second program of this webinar series expands upon issues impacting biologics and biosimilar development, including FDA regulatory issues and interfacing with the FDA before any applications are filed, decisions concerning the types of evidence that are likely to be required to obtain FDA approval, and the FDA’s guidance on naming and labeling of biosimilar products.
Moderator:
Basil “Bill” J. Lewris
Alissa K. Lipton
Linda A. Wadler
Friday, February 17, 2017
10:00 - 11:00 a.m. PST
1:00 - 2:00 p.m. EST
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Webinar
February 15, 2024
Webinar
Webinar
Navigating Your Life Sciences Opposition: Tips for Best Practice When You Are Opposing or Opposed
December 12, 2023
Webinar
Conference
23rd Annual Charting Your Own Course Career Development Conference
December 7-10, 2023
Orlando
Nickel and Dimed: Recent Regulatory Developments on Pricing Claims
November 30, 2023
Webinar
Webinar
November 30 2023
Webinar
Webinar
November 28, 2023
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.